mg twice daily. At the time of the call, she was taking 3 mg twice daily (0.1 mg/kg/d). The immunosuppressive properties of tacrolimus and the existence of only 1 case series reporting its excretion into human milk were explained to the patient, and contrasted with the potential benefits of breast-feeding and the fact that she had taken the medication throughout pregnancy. She decided that, depending on the health of the baby following delivery, she would initiate breast-feeding and asked us to estimate the infant exposure to the drug by measuring tacrolimus concentrations in her milk.
Manually expressed milk samples were collected at 0 (trough), 1, 6, 9, 11 , and 12 hours after the morning dose, as well as maternal blood samples at 0 and 1 hour. The samples were stored at -20˚C until analysis by tandem-mass spectrometry (tandem-MS/MS) at the Children's National Medical Center (Washington, DC) within 8 days. The Sciex API-2000 instrument (MDS Sciex, Toronto, Canada) was used for whole-blood and human milk analysis, as described previously. 3 A minor modification to the whole-blood method was required for human milk analysis; following deproteinization, 120 µL (4 times the amount of sample stated in the published whole-blood method) was injected for analysis. This step was necessary to enhance the signal and increase the sensitivity of the method. Other than this modification, the technique for measurement of tacrolimus in human milk is the same as for whole blood. The coefficient of variation at 6 and 0.3 ng/mL is 4% and 20%, respectively. The limit of sensitivity is 0.2 ng/mL, and the injection volume was quadrupled to enhance sensitivity.
The AUC of tacrolimus in milk from time 0 to 12 hours of the dose was calculated by the trapezoidal method. The elimination half-life (t 1/2 ) of tacrolimus in breast milk was calculated using the slope of the elimination phase of the AUC.
By multiplying the AUC of tacrolimus in milk with an assumed infant's milk intake of 150 mL/kg/d, an infant daily exposure to tacrolimus through breast-feeding was estimated. A hypothetical maximum infant dose was calculated based on the highest measured drug concentration in milk.
Results
The highest concentration of tacrolimus in milk (0.57 ng/mL) was observed at 1-hour after the dose (Figure 1 ). This concentration is not necessarily the actual peak concentration of tacrolimus in human milk, as we were limited by the mother's ability to express milk. The first 2 samples were scheduled, but the remaining samples were drawn based on the feeding times. A more accurate estimate of peak concentration would be obtained if milk samples were taken at 0, 1, 2, 4, 6, and 8 hours after the dose. The AUC and the mean concentration were calculated to be 5.15 h • ng/mL and 0.429 ng/mL, respectively. Therefore, the tacrolimus dose this exclusively breastfed infant would ingest was 0.06 µg/kg/d (0.429 ng/mL × 150 mL/kg/d), which is 0.06% of the mother's weight-adjusted dose (0.1 mg/kg/d). A maximum tacrolimus dose the infant would receive through breast-feeding is 0.09 µg/kg/d, which corresponds to about 0.09% of the mother's weight-adjusted dose. Oral bioavailability of tacrolimus has been reported 4 to range from 18% in healthy volunteers to 34% in pediatric liver transplant patients. Using the highest range of bioavailability, the baby could potentially absorb 0.02% of the mother's weight-adjusted dose.
The maternal whole-blood concentrations of tacrolimus were 6.5 and 6.6 ng/mL at 0 and 1 hour, respectively. Using the human milk concentrations of tacrolimus at the corresponding times, the milk-to-whole-blood ratio of tacrolimus was 0.08 and 0.09, respectively. We are not sure why the difference between the pre-dosing and 1-hour post-dosing maternal whole-blood tacrolimus concentrations is not great. It is likely due to steady-state pharmacokinetics.
The apparent t 1/2 of tacrolimus in breast milk was calculated to be 12.85 hours. The t 1/2 of tacrolimus in the patient could not be calculated from the available data because only 2 concentrations could be obtained from the patient, but it is approximately 11.7 hours in liver transplant patients and 34.2 hours in healthy volunteers. The t 1/2 is usually calculated after single-dose administration or after the last dose in steady-state. We clearly did not have these conditions, and hence could not sample for 3-5 half-lives to characterize the elimination. Therefore, the value we calculated for the t 1/2 of tacrolimus in breast milk should be interpreted with caution. At 2.5 months of age, the infant was developing well both physically and neurologically. His weight and supine length were at the 50th percentile, as was his head circumference. He holds his head up and smiles. Chest ultrasound revealed a normally developed thymus.
Discussion
Tacrolimus concentration in breast milk has been reported previously in 1 other study. 2 This group measured tacrolimus concentrations in the colostrum of 6 mothers who had taken the medication throughout pregnancy, but had been advised not to breast-feed their infants. The authors found that the average concentration of tacrolimus in the 816 ■ The Annals of Pharmacotherapy ■ 2003 June, Volume 37 www.theannals.com AE French et al. first breast milk specimen was 0.6 ng/mL. This corresponds with the peak concentration measured in our patient's breast milk, which is reassuring. Several elements of this small case series, however, may limit the results. 2 First, we disagree with the authors' method of tacrolimus measurement. Concentrations were measured in the colostrum, the first breast milk specimen, which is known to differ in protein content from mature milk. 5, 6 The elevated protein levels could theoretically change the way in which tacrolimus is handled by the human milk. Second, an immunoassay was used in the mentioned study for analysis of tacrolimus concentrations in breast milk. 2 Immunoassays for tacrolimus have problems with specificity and cross-reactivity with metabolites, which can result in overestimation of the concentration of the parent compound. 7-10 Additionally, all concentrations reported from this case series were <9 ng/mL. Ghoshal and Soldin 11 recently found that the IMx tacrolimus II assay (which is still used in >99% of laboratories in North America) is not accurate for concentrations of tacrolimus <9 ng/mL. Tandem-MS/MS is a far more sensitive and specific method for tacrolimus measurement because there is no metabolite interference and better sensitivity. Lastly, all of the mothers were counseled to abstain from breast-feeding while taking the medication; in our case, the mother breast-fed while continuing the medication, so we have been able to follow up with the infant's development.
Summary
Our report is the first to measure tacrolimus concentrations in established human milk (rather than colostrum) using tandem-MS/MS to detect the drug while the mother was exclusively breast-feeding the infant, and in which the infant's growth and development were reported. Our study may be somewhat limited by lack of a milk sample between 1 and 6 hours after the dose, due to the schedule of feeding the baby. We determined that the exclusively breast-fed infant would ingest only 0.06% of the mother's weight-adjusted dose of tacrolimus. While more data are needed, our results along with those in a previous study suggest that maternal therapy with tacrolimus for liver transplant may be compatible with breast-feeding. EXTRACTO OBJETIVO: Reportar el primer caso de medición de tacrolimus en leche humana de una madre que usaba el fármaco para transplante de hígado mientras lactaba al infante.
REPORTE DEL CASO:
Una mujer de 32 años de edad que había tomado tacrolimus (0.1 mg/kg/d) a través del embarazo contactó el Programa de Riesgo de Maternidad a las 35 semanas de gestación. Ella preguntó sobre la seguridad de lactar mientras recibía terapia con tacrolimus. Luego de una evaluación riesgo-beneficio, la madre decidió lactar a su bebé.
MÉTODOS:
Se tomaron manualmente muestras de leche por un período de 12 horas luego de la primera dosis del día. Además, se tomaron muestras de sangre en la madre antes y 1 hora después de la dosis del fármaco. La medición de tacrolimus en las muestras se hizo por el sistema tandem -MS/MS. Las muestras de leche y sangre se tomaron en estado estacionario.
RESULTADOS:
Las concentraciones máximas y promedio de tacrolimus en la leche fueron de 0.57 y 0.429 ng/mL, respectivamente. De estas mediciones, el infante alimentado exclusivamente de leche materna ingeriría un promedio de 0.06 µg/kg/d. Esto corresponde a 0.06% de la dosis ajustada al peso de la madre. La cantidad máxima que el infante recibiría es 0.02% de la dosis ajustada al peso de la madre dada la biodisponibilidad oral baja de tacrolimus. La razón leche a sangre de tacrolimus en la concentración pre-dosis y 1 hora después de la dosis fue calculada en 0.08 y 0.09, respectivamente. A los 2.5 meses de edad, el infante se estaba desarrollando bien tanto física como neurológicamente. COMENTARIO: Este es el primer reporte de medición de concentraciones de tacrolimus en leche humana usando el sistema tandem -MS/MS para detectar el fármaco mientras el infante se alimentaba exclusivamente de la leche materna. Este también es el primer caso en que se reporta el crecimiento y desarrollo del infante.
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CONCLUSIONES:
Los resultados obtenidos sugieren que la terapia materna con tacrolimus para transplante de hígado puede ser compatible con la lactancia.
Juan F Feliú RÉSUMÉ OBJECTIF: Rapporter les concentrations de tacrolimus dans le lait maternel d'une patiente ayant décidé de poursuivre son traitement immunosuppresseur durant l'allaitement de son enfant. RÉSUMÉ DU CAS: Une patiente âgée de 32 ans ayant pris le tacrolimus à raison de 0.1 mg/kg/j durant toute sa grossesse a contacté le centre d'information mère -enfant de l'hôpital Sick Children pour s'enquérir de l'innocuité du tacrolimus durant l'allaitement maternel. Après avoir considéré les bénéfices et les risques pour son enfant, la patiente décide de débuter l'allaitement. Elle demande aux professionnels du centre mère-enfant d'estimer l'exposition de son enfant au tacrolimus en mesurant les concentrations du médicament dans son lait maternel. MÉTHODOLOGIE: Des échantillons de lait maternel ont été collectés manuellement pendant une période de 12 heures suivant l'administration du tacrolimus tandis que des prélèvements sanguins ont été faits tout juste avant l'administration du tacrolimus ainsi qu'une heure post-dose. Ces échantillons, recueillis à l'état d'équilibre, ont été analysés par spectrométrie de masse en tandem.
RÉSULTATS: La concentration sanguine maximale du tacrolimus dans le lait maternel était de 0.57 ng/mL alors que sa concentration moyenne était de 0.429 ng/mL. Selon ces concentrations et les calculs d'aire sous la courbe, il a été possible d'estimer que cet enfant nourri exclusivement au sein était exposé à 1 dose de 0.06 µg/kg/j, ce qui correspond à environ 0.06% de la dose maternelle. Considérant la faible biodisponibilité orale du tacrolimus, la quantité maximale du tacrolimus que l'enfant pourrait absorber serait donc de 0.02% de la dose maternelle. Le rapport lait/sang entier du tacrolimus à l'heure 0 (prédose) et à une heure post-dose était respectivement de 0.08 et de 0.09. Un suivi médical a été fait auprès de l'enfant à l'âge de deux mois et demi et l'enfant semblait bien se développer tant au niveau physique qu'au niveau neurologique. DISCUSSION: Cet article est la première publication faisant état des concentrations de tacrolimus dans le lait maternel alors que le traitement immunosuppresseur est poursuivi durant l'allaitement maternel et que des données au niveau de la croissance et du développement de l'enfant allaité sont rapportées.
CONCLUSIONS:
Les résultats des auteurs suggèrent que la poursuite du tacrolimus durant l'allaitement maternel semble être une option thérapeutique possible.
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